human
blood
plasma
report
possess
antivir
activ
activ
due
sever
preexist
natur
occur
molecul
either
activ
individu
member
famili
virus
molecul
howev
adequ
studi
reveal
molecular
structur
mechan
action
presum
low
antivir
action
therefor
possibl
role
viraemia
remain
unknown
recent
two
natur
occur
broadspectrum
antivir
agent
univers
texa
inhibitor
b
utib
glycoprotein
high
densiti
lipoprotein
describ
human
serum
activ
dna
rna
virus
one
utib
possess
antivir
activ
unitsml
sinc
preexist
antivir
molecul
serum
appear
defenc
mechan
avail
onset
viral
infect
may
protect
viraemia
view
potenti
undertaken
review
properti
innat
viral
inhibitori
molecul
innat
resist
mechan
import
barrier
pathogen
particularli
maintain
initi
critic
balanc
onset
infect
repres
conglomer
mechan
barrier
cellular
reaction
molecul
antimicrobi
activ
consid
antivir
molecul
report
occur
human
serum
viraemia
import
mode
viral
spread
target
organ
bodi
normal
human
serum
report
possess
inhibitori
activ
particular
virus
individu
group
virus
antivir
activ
resid
varieti
uncharacteris
partli
characteris
substanc
recent
certain
molecul
normal
human
serum
describ
activ
broad
spectrum
virus
molecul
characteris
antivir
activ
molecular
structur
mechan
antivir
action
review
emphasis
properti
broadli
activ
antivir
molecul
human
serum
explor
possibl
import
natur
defenc
mechan
note
innat
antivir
activ
resid
varieti
uncharacteris
partli
characteris
substanc
distinguish
antibodi
interferon
complement
mani
antivir
substanc
gener
report
act
singl
virus
coronaviru
newcastl
diseas
viru
variola
viru
sendai
viru
vesicular
stomat
viru
activ
individu
viru
famili
includ
myxovirus
togavirus
retrovirus
mechan
action
viral
inhibitor
known
vari
act
irrevers
neutralis
infect
case
coronaviru
sendai
viru
inhibitor
myxoand
togaviru
inhibitor
appear
prevent
haemagglutin
infect
inhibitor
vesicular
stomat
viru
act
penetr
viral
envelop
inactiv
viral
rna
retroviru
inhibitor
work
via
complement
mediat
lysi
viral
infect
cell
heparin
may
use
medic
prevent
clot
narrow
antivir
activ
deserv
mention
potent
activ
four
broadspectrum
viral
inhibitor
report
human
sera
ifn
tnf
occur
respons
infect
cancer
other
constitut
ie
utib
highdens
lipoprotein
hdl
antivir
activ
present
tabl
antivir
activ
determin
plaqu
reduct
assay
describ
previous
assay
done
duplic
use
continu
presenc
serial
dilut
test
substanc
microtitr
plate
ent
cell
monolay
challeng
pfu
viru
one
unit
u
antivir
activ
reciproc
highest
dilut
inhibitor
show
reduct
plaqu
compar
viru
control
refer
viru
inhibitor
standard
use
assay
posit
control
virus
use
studi
origin
nation
institut
health
bethesda
md
except
coxsacki
viru
obtain
dr
charl
j
gaunt
univers
texa
health
scienc
center
san
antonio
tx
vero
cell
african
green
monkey
kidney
cell
american
type
cultur
collect
use
assay
virus
except
vaccinia
viru
cer
chicken
embryo
reticulocyt
receiv
laboratori
dr
robert
shope
yale
univers
ct
time
use
broad
antivir
activ
may
import
featur
antivir
defenc
tabl
show
utib
hdl
inhibit
virus
test
includ
dna
envelop
nonenvelop
rna
virus
howev
utib
activ
hiv
unpublish
inhibitori
activ
utib
usual
greater
hdl
viru
utib
appear
account
antivir
activ
human
serum
two
prepar
hdl
compar
except
prepar
dr
g
ananthramiah
depart
medicin
biochemistri
molecular
genet
arthrosclerosi
research
unit
univers
alabama
birmingham
birmingham
al
usa
inact
polioviru
differ
could
due
extent
process
use
differ
method
determin
enzymat
utib
glycoprotein
r
approxim
base
hplc
size
exclus
chromatographi
antivir
activ
stabl
ph
min
mild
oxid
sodium
period
glycolysi
mixtur
glycosidas
destroy
antivir
activ
proteinas
digest
degrad
inhibitor
small
compon
r
retain
broad
antivir
activ
activ
small
compon
increas
heat
stabil
min
still
inactiv
glycosidas
thu
antivir
activ
appear
resid
mainli
separ
oligosaccharid
moieti
glycoprotein
utib
human
serum
hdl
lipoprotein
r
occur
serum
rang
mgdl
antivir
properti
seem
resid
protein
compon
apolipoprotein
apolipoprotein
report
inhibit
hiv
shown
tabl
hdl
broadli
activ
dna
envelop
nonenvelop
rna
virus
mode
inhibit
viru
growth
determin
investig
whether
inhibit
result
direct
revers
neutralis
virion
inhibit
viru
attach
cell
inhibit
viral
penetr
cell
effect
later
viru
multipl
cycl
revers
inhibit
viral
infect
determin
mix
inhibitor
prepar
viru
suspens
incub
mixtur
h
incub
mixtur
dilut
beyond
inhibitori
level
determin
residu
titr
infecti
viru
irrevers
neutralis
inhibitor
result
indic
utib
hdl
irrevers
inactiv
either
envelop
nonenvelop
virus
possibl
inhibit
viru
attach
target
cell
examin
compar
inhibitori
titr
h
viru
attach
h
viru
attach
penetr
viru
challeng
dose
pfu
use
infect
monolay
cell
microtitr
plate
two
temperatur
cultur
wash
three
time
hank
balanc
salt
solut
hbss
overlaid
methylcellulos
hepe
buffer
mc
plaqu
stain
crystal
violet
read
day
rational
experi
cell
membran
physiolog
inert
henc
viru
replic
proceed
beyond
initi
attach
target
cell
equal
antivir
activ
titr
impli
antivir
substanc
activ
therefor
act
stage
viru
attach
target
cell
inhibitor
act
postattach
stage
result
higher
titr
shown
tabl
titr
utib
virus
use
except
statist
indistinguish
case
inhibitori
titr
uml
occur
compar
uml
indic
inhibit
replic
step
subsequ
adsorpt
comparison
case
hdl
sindbi
mengo
viru
attach
inhibit
indic
hdl
inhibit
postattach
step
viru
replic
studi
possibl
hdl
prevent
penetr
viru
cell
method
previous
describ
follow
allow
viru
attach
cell
precool
h
microtitr
plate
infect
pfu
sindbi
mengo
viru
h
cold
allow
viru
attach
cell
wash
twice
cold
hbss
remov
unabsorb
viru
cell
warm
initi
viru
penetr
h
presenc
serial
twofold
dilut
inhibitor
allow
inhibitori
effect
occur
time
penetr
cultur
wash
hbss
refe
eagl
minimum
essenti
medium
emem
contain
fetal
bovin
serum
fb
well
ml
contain
uml
antibodi
viru
ad
neutralis
viru
held
extracellularli
hdl
cell
incub
h
wash
refeed
antibodi
control
show
effect
antibodi
neutralis
h
cell
wash
twice
hbss
layer
mc
incub
plaqu
develop
plaqu
count
percent
inhibit
plaqu
rel
control
calcul
indic
inhibit
viru
event
stage
viru
penetr
result
tabl
show
cell
infect
presenc
hdl
consist
retain
viru
surfac
evidenc
effect
neutralis
antibodi
ad
h
start
incub
hdl
thu
presenc
hdl
viru
attach
occur
penetr
occur
time
inhibit
viru
replic
growth
cycl
determin
describ
previous
inhibitor
prepar
ad
variou
time
onestep
growth
cycl
viru
viru
yield
determin
singl
cycl
harvest
viru
h
synchronis
initi
viru
replic
design
h
obtain
infect
monolay
viru
cultur
plate
h
allow
attach
viru
cell
wash
three
time
cold
emem
remov
unabsorb
viru
inhibitor
refe
warm
inhibitor
emem
contain
fb
incub
complet
singl
cycl
viru
replic
h
cultur
store
viru
yield
quadrupl
well
pool
viru
plaqu
assay
viru
yield
calcul
pfu
endpoint
result
shown
figur
indic
inhibit
sindbi
viru
occur
princip
hdl
ad
h
growth
cycl
earli
inhibit
indic
antivir
action
hdl
occur
earli
viru
growth
cycl
consist
inhibit
viral
penetr
determin
preced
section
possibl
induct
serum
inhibitor
durabl
antivir
state
cell
eg
similar
ifn
utib
hdl
determin
serial
dilut
inhibitor
cell
monolay
incub
overnight
cell
wash
main
broadspectrum
viral
inhibitor
serum
utib
lesser
degre
hdl
preincub
viru
utib
hdl
reduc
infect
indic
bind
irrevers
virion
irrevers
neutralis
infect
similarli
preincub
cell
hdl
utib
unlik
ifn
induc
antivir
state
cell
inhibit
experi
reveal
utib
inhibit
viru
prevent
viru
attach
type
experi
show
hdl
hand
act
virus
postattach
stage
investig
mechan
viral
inhibit
hdl
indic
hdl
inhibit
multipl
cycl
earli
stage
h
initi
like
prevent
penetr
cell
surfac
viru
vivo
studi
protect
role
broadspectrum
serum
inhibitor
done
howev
one
report
vivo
protect
effect
broadli
activ
viru
inhibitor
found
vertebr
nervou
system
protect
inhibitortr
mice
demonstr
alphaviru
picornaviru
tabl
base
protect
correl
author
suggest
natur
defens
role
broadli
antivir
inhibitor
present
wide
high
concentr
tissu
human
nervou
system
similar
vivo
protect
studi
done
serum
inhibitor
possibl
defens
role
narrowli
activ
serum
inhibitor
natur
resist
review
kriznova
rathova
mechan
action
inhibitor
competit
inhibit
viru
attach
cell
neutralis
viral
infect
mechan
unlik
classic
antibodi
complement
need
activ
variou
approach
undertaken
elucid
possibl
role
serum
inhibitor
natur
resist
organ
group
three
categori
categori
effort
made
correl
suscept
experiment
anim
particular
viru
natur
inhibitori
activ
sera
correl
show
experiment
anim
use
resist
sever
strain
viru
innat
serum
inhibitor
strain
present
sera
second
categori
effort
made
measur
effect
suppress
delet
serum
inhibitor
suscept
experiment
anim
viru
infect
sever
experi
shown
mice
hamster
fed
ethionin
appreci
reduc
viru
inhibitori
activ
serum
newcastl
diseas
virus
untreat
observ
point
relationship
vivo
level
serum
inhibitor
viru
multipl
thu
support
notion
narrowli
activ
viral
inhibitor
factor
innat
resist
virus
third
categori
assess
direct
effect
administ
inhibitor
differ
time
viral
infect
experiment
anim
administ
inhibitor
prepar
differ
interv
either
immedi
viru
inocul
use
gamma
serum
inhibitor
shown
multipl
inhibitorsensit
strain
viru
mice
lung
inhibit
effect
seen
inhibitor
administ
viru
time
penetr
suscept
cell
inhibitor
viru
administ
intranas
gamma
inhibitor
given
intranas
h
postinfect
later
protect
high
dose
inhibitor
given
ip
even
longer
interv
infect
show
appreci
protect
effect
satisfactori
explan
appear
overal
gamma
inhibitor
function
defenc
mechan
condit
compar
properti
mechan
action
constitut
utib
hdl
induc
ifn
tnf
inhibitor
import
broadli
activ
defenc
viraemia
tabl
compar
properti
inhibitor
show
constitut
viru
inhibitor
utib
hdl
clearli
distinct
induc
ifn
tnf
defenc
innat
antivir
substanc
present
human
plasma
care
explor
natur
defenc
viraemia
infect
review
indic
plasma
contain
sever
natur
occur
antivir
substanc
broadli
activ
wide
rang
dna
envelop
nonenvelop
rna
virus
mechan
action
broadli
activ
utib
occur
viru
attach
hdl
viru
penetr
limit
studi
vivo
protect
role
antivir
substanc
indic
import
infect
particularli
earli
stage
infect
reactiv
host
defenc
like
ifn
immun
induc
studi
need
area
virolog
